**Chapter 10**

*Acute Leukemias*

2017;**35**(24):2754-2763

[34] Ohtake S et al. *Randomized study of induction therapy comparing standard-dose idarubicin with highdose daunorubicin in adult patients with previously untreated acute myeloid leukemia: The JALSG AML201 study*. Blood. 2011;**117**(8):2358-2365

[35] Pautas C et al. *Randomized study of intensified anthracycline doses for induction and recombinant interleukin-2* 

[36] Chevallier P et al. *Tandem versus single autologous peripheral blood stem cell transplantation as post-remission therapy in adult acute myeloid leukemia patients under 60 in first complete remission: Results of the multicenter prospective phase III GOELAMS LAM-2001 trial*. Leukemia. 2010;**24**(7):1380-1385

[37] Récher C et al. *Long-term results of a randomized phase 3 trial comparing idarubicin and daunorubicin in younger patients with acute myeloid leukaemia*. Leukemia. 2014;**28**(2):440-443

[38] Gardin C et al. *Postremission treatment of elderly patients with acute myeloid leukemia in first complete remission after intensive induction chemotherapy: Results of the multicenter randomized acute leukemia French association (ALFA) 9803 trial*. Blood.

[39] Gardin C et al. *Superior long-term outcome with idarubicin compared with high-dose daunorubicin in patients with acute myeloid leukemia age 50 years and* 

2007;**109**(12):5129-5135

*for maintenance in patients with acute myeloid leukemia age 50 to 70 years: Results of the ALFA-9801 study*. Journal of Clinical Oncology.

2010;**28**(5):808-814

[33] Lee JH et al. *Prospective randomized comparison of Idarubicin and high-dose daunorubicin in induction chemotherapy for newly diagnosed acute myeloid leukemia*. Journal of Clinical Oncology. *older*. Journal of Clinical Oncology.

[40] Owattanapanich W et al. *Efficacy and toxicity of Idarubicin versus high-dose daunorubicin for induction chemotherapy in adult acute myeloid leukemia: A systematic review and meta-analysis*. Clinical Lymphoma, Myeloma & Leukemia. 2018;**18**(12):814-821.e3

[41] Mandelli F et al. *Daunorubicin versus mitoxantrone versus idarubicin as induction and consolidation chemotherapy for adults with acute myeloid leukemia: The EORTC and GIMEMA groups study AML-10*. Journal of Clinical Oncology.

[42] Rowe JM et al. *A phase 3 study of three induction regimens and of priming with GM-CSF in older adults with acute myeloid leukemia: A trial by the eastern cooperative oncology group*. Blood.

[43] Alfayez M et al. *CPX-351 (vyxeos) in AML*. Leukemia & Lymphoma.

[44] Tzogani K et al. *EMA review of daunorubicin and cytarabine encapsulated in liposomes (Vyxeos, CPX-351) for the treatment of adults with newly diagnosed, therapy-related acute myeloid leukemia or acute myeloid leukemia with Myelodysplasia-related changes*. The Oncologist. 2020;**25**(9):e1414-e1420

2009;**27**(32):5397-5403

2004;**103**(2):479-485

2020;**61**(2):288-297

2013;**31**(3):321-327

**164**
